LOH in the HLA Class I Region at 6p21 is Associated with Shorter Survival in Newly Diagnosed Adult Glioblastoma

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2013 Feb 13

PMID 23401227

Citations 47

Authors

Jacky T Yeung

Ronald L Hamilton

Koji Ohnishi

Maki Ikeura

Douglas M Potter

Marina N Nikiforova

Soldano Ferrone

Regina I Jakacki

Ian F Pollack

Hideho Okada

Affiliations

Soon will be listed here.

Abstract

Purpose: Glioblastoma (GBM) shows downregulated expression of human leukocyte antigen (HLA) class I, thereby escaping from cytotoxic T cells and limiting the efficacy of immunotherapy. Loss of heterozygosity (LOH) of HLA class I (6p21) and/or β-2 microglobulin (B2m) (15q21) regions represents irreversible downregulation. In this study, we examined the prevalence of these LOH events and their relations with overall survival in GBM.

Experimental Design: In a cross-sectional analysis on 60 adult patients with GBM, DNA from formalin-fixed, paraffin-embedded specimens were evaluated for 10 microsatellite regions of HLA class I, B2m, HLA class II, HLA class III, and 6q by PCR as well as immunohistochemical evaluation of HLA class I expression and CD8(+) T-cell infiltration.

Results: LOH in HLA class I, B2m, HLA class II, HLA class III, and 6q regions was present in 41.4%, 18.2%, 9.4%, 77.8%, and 36.0% of informative cases, respectively. LOH of HLA class I was associated with shorter overall survival (HR = 4.89, P = 0.0078). HLA class I was downregulated in 22% to 43% of cases based on immunohistochemistry. Cases that displayed negative staining were significantly younger. HLA class I expression correlated with intratumoral CD8(+) T-cell infiltration.

Conclusion: LOH in the HLA class I region is frequent in adult GBMs. The association of shorter survival with LOH in this region suggests a crucial role for these genes in immunosurveillance.

Citing Articles

Loss of Heterozygosity (LOH) Affecting HLA Genes in Breast Cancer: Clinical Relevance and Therapeutic Opportunities.

Garrido M, Navarro-Ocon A, Ronco-Diaz V, Olea N, Aptsiauri N Genes (Basel). 2025; 15(12.

PMID: 39766811 PMC: 11675875. DOI: 10.3390/genes15121542.

Chimeric antigen receptor T-cell therapy in patients with malignant glioma-From neuroimmunology to clinical trial design considerations.

Gallus M, Young J, Cook Quackenbush S, Khasraw M, de Groot J, Okada H Neuro Oncol. 2024; 27(2):352-368.

PMID: 39450490 PMC: 11812040. DOI: 10.1093/neuonc/noae203.

NKG2C/ tumor cell expression enhances immunotherapeutic efficacy against glioblastoma.

de Dios O, Ramirez-Gonzalez M, Gomez-Soria I, Segura-Collar B, Manosalva J, Megias D J Immunother Cancer. 2024; 12(8).

PMID: 39214651 PMC: 11367385. DOI: 10.1136/jitc-2024-009210.

A systematic review of immunotherapy in high-grade glioma: learning from the past to shape future perspectives.

Sferruzza G, Consoli S, Dono F, Evangelista G, Giugno A, Pronello E Neurol Sci. 2024; 45(6):2561-2578.

PMID: 38308708 DOI: 10.1007/s10072-024-07350-w.

Glioblastoma vaccines: past, present, and opportunities.

Xiong Z, Raphael I, Olin M, Okada H, Li X, Kohanbash G EBioMedicine. 2024; 100:104963.

PMID: 38183840 PMC: 10808938. DOI: 10.1016/j.ebiom.2023.104963.

References

. 12th International Histocompatibility Conference. Genetic diversity of HLA: functional and medical implications. Paris, France, June 9-12, 1996. Abstracts. Hum Immunol. 1996; 47(1-2):1-184. View

Tanabe K, Matsushima-Nishiwaki R, Yamaguchi S, Iida H, Dohi S, Kozawa O . Mechanisms of tumor necrosis factor-alpha-induced interleukin-6 synthesis in glioma cells. J Neuroinflammation. 2010; 7:16. PMC: 2846903. DOI: 10.1186/1742-2094-7-16. View

Satoh E, Mabuchi T, Satoh H, Asahara T, Nukui H, Naganuma H . Reduced expression of the transporter associated with antigen processing 1 molecule in malignant glioma cells, and its restoration by interferon-gamma and -beta. J Neurosurg. 2006; 104(2):264-71. DOI: 10.3171/jns.2006.104.2.264. View

Hobbs J, Nikiforova M, Fardo D, Bortoluzzi S, Cieply K, Hamilton R . Paradoxical relationship between the degree of EGFR amplification and outcome in glioblastomas. Am J Surg Pathol. 2012; 36(8):1186-93. PMC: 3393818. DOI: 10.1097/PAS.0b013e3182518e12. View

Maleno I, Cabrera C, Cabrera T, Paco L, Lopez-Nevot M, Collado A . Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Immunogenetics. 2004; 56(4):244-53. DOI: 10.1007/s00251-004-0692-z. View

Liu Y, Komohara Y, Domenick N, Ohno M, Ikeura M, Hamilton R . Expression of antigen processing and presenting molecules in brain metastasis of breast cancer. Cancer Immunol Immunother. 2011; 61(6):789-801. PMC: 3365630. DOI: 10.1007/s00262-011-1137-9. View

Garrido C, Paco L, Romero I, Berruguilla E, Stefansky J, Collado A . MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells. Carcinogenesis. 2012; 33(3):687-93. DOI: 10.1093/carcin/bgr318. View

Garrido C, Algarra I, Maleno I, Stefanski J, Collado A, Garrido F . Alterations of HLA class I expression in human melanoma xenografts in immunodeficient mice occur frequently and are associated with higher tumorigenicity. Cancer Immunol Immunother. 2009; 59(1):13-26. PMC: 11031073. DOI: 10.1007/s00262-009-0716-5. View

Maleno I, Lopez-Nevot M, Cabrera T, Salinero J, Garrido F . Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunol Immunother. 2002; 51(7):389-96. PMC: 11032975. DOI: 10.1007/s00262-002-0296-0. View

10.

Healy E, Belgaid C, Takata M, Harrison D, Zhu N, Burd D . Prognostic significance of allelic losses in primary melanoma. Oncogene. 1998; 16(17):2213-8. DOI: 10.1038/sj.onc.1200203. View

11.

Chuaqui R, Silva M . Allelic deletion mapping on chromosome 6q and X chromosome inactivation clonality patterns in cervical intraepithelial neoplasia and invasive carcinoma. Gynecol Oncol. 2001; 80(3):364-71. DOI: 10.1006/gyno.2000.6087. View

12.

Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-96. DOI: 10.1056/NEJMoa043330. View

13.

Slebos R, Umbach D, Sommer C, Horner G, Choi J, Taylor J . Analytical and statistical methods to evaluate microsatellite allelic imbalance in small amounts of DNA. Lab Invest. 2004; 84(5):649-57. DOI: 10.1038/labinvest.3700076. View

14.

Garrido F, Algarra I, Garcia-Lora A . The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible "hard" lesions. Cancer Immunol Immunother. 2010; 59(10):1601-6. PMC: 11029827. DOI: 10.1007/s00262-010-0893-2. View

15.

Miyakawa A, Ichimura K, Schmidt E, Collins V . Multiple deleted regions on the long arm of chromosome 6 in astrocytic tumours. Br J Cancer. 2000; 82(3):543-9. PMC: 2363324. DOI: 10.1054/bjoc.1999.0961. View

16.

Mohapatra G, Kim D, Feuerstein B . Detection of multiple gains and losses of genetic material in ten glioma cell lines by comparative genomic hybridization. Genes Chromosomes Cancer. 1995; 13(2):86-93. DOI: 10.1002/gcc.2870130203. View

17.

Lohr J, Ratliff T, Huppertz A, Ge Y, Dictus C, Ahmadi R . Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-β. Clin Cancer Res. 2011; 17(13):4296-308. DOI: 10.1158/1078-0432.CCR-10-2557. View

18.

Kloetzel P . The proteasome and MHC class I antigen processing. Biochim Biophys Acta. 2004; 1695(1-3):225-33. DOI: 10.1016/j.bbamcr.2004.10.004. View

19.

Raffaghello L, Nozza P, Morandi F, Camoriano M, Wang X, Garre M . Expression and functional analysis of human leukocyte antigen class I antigen-processing machinery in medulloblastoma. Cancer Res. 2007; 67(11):5471-8. DOI: 10.1158/0008-5472.CAN-06-4735. View

20.

Yang I, Tihan T, Han S, Wrensch M, Wiencke J, Sughrue M . CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival. J Clin Neurosci. 2010; 17(11):1381-5. PMC: 3064460. DOI: 10.1016/j.jocn.2010.03.031. View